Skip to main content
Pharma Mar S.A. logo

Pharma Mar S.A. — Investor Relations & Filings

Ticker · PHM ISIN · ES0169501022 LEI · 959800QWKZ45ZQC2AV58 MC Manufacturing
Open in API
Filings indexed 351 across all filing types
Latest filing 2023-02-28 Audit Report / Informat…
Country ES Spain
Listing MC PHM

About Pharma Mar S.A.

https://pharmamar.com/en/

Pharma Mar S.A. is a biopharmaceutical company specializing in the discovery, development, and commercialization of oncology treatments derived from marine sources. A pioneer in its field since 1986, the company leverages marine biodiversity to develop innovative therapies for cancer, with a particular focus on rare tumors. Its integrated R&D pipeline spans from the exploration of marine invertebrates to the marketing of approved drugs. The company maintains an extensive collection of over 500,000 marine samples, which serves as the foundation for its drug discovery programs. Key commercialized products include Yondelis® (trabectedin) for advanced soft tissue sarcoma and ovarian cancer, Zepzelca® (lurbinectedin) for small cell lung cancer, and Aplidin® (plitidepsin) for multiple myeloma.

Recent filings

Filing Released Lang Actions
Audit Report / Information 2022
Audit Report / Information Classification · 98% confidence The document contains detailed financial tables titled 'Balance sheet as of 2022 year-end', 'Statement of income for the year ended 31 December 2022', and 'Statement of changes in equity for the year ended 31 December 2022'. These components—Balance Sheet, Income Statement, and Statement of Changes in Equity—are the core elements of a comprehensive annual financial report. Although the text does not explicitly use the term '10-K', the structure and content strongly indicate a full-year financial filing, which corresponds to the Annual Report category (10-K). The document length is substantial (over 350,000 characters), confirming it is the report itself, not just an announcement (ruling 2 does not apply). FY 2022
2023-02-28 Spanish
Annual Report 2022
Annual Report Classification · 100% confidence The document is a comprehensive financial report titled 'Consolidated Financial Statements and Consolidated Directors' Report as of 31 December 2022'. It contains detailed financial statements, including the Consolidated Balance Sheet, Consolidated Income Statement, Statement of Comprehensive Income, and Statement of Changes in Equity. It also includes audit-related commentary (Key Audit Matters). As it covers a full fiscal year and provides substantive financial data, it is classified as an Annual Report (10-K). FY 2022
2023-02-28 Spanish
Annual Report 2022
Annual Report Classification · 100% confidence The document contains consolidated annual financial statements including balance sheets, income statements, and comprehensive income statements for the fiscal year ended December 31, 2022. It includes detailed financial data such as assets, liabilities, equity, revenues, expenses, and earnings per share. The presence of full financial statements and notes indicates this is a comprehensive yearly report covering company activity and financial performance. The document length is substantial (15,000 characters), and it is not merely an announcement or certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2022
2023-02-28 Spanish
La Sociedad anuncia el cierre del estudio de fase III Neptuno con plitidepsina para el tratamiento de la COVID-19 en pacientes hospitalizados.
Legal Proceedings Report Classification · 99% confidence The document is a formal communication addressed to the 'Comisión Nacional del Mercado de Valores' (CNMV, the Spanish securities market regulator) and is explicitly labeled as 'INFORMACIÓN PRIVILEGIADA' (Inside Information/Privileged Information). It announces a specific corporate event: the closure of a Phase III clinical study (Neptuno) due to recruitment issues, and mentions that a press release is attached. This type of mandatory disclosure of material, non-public information to the regulator, which is not a standard periodic report (like 10-K or IR), falls best under the general category for regulatory announcements that don't fit elsewhere, which is 'Regulatory Filings' (RNS). Although it contains elements of a press release, its primary function here is regulatory disclosure of inside information.
2023-02-16 Spanish
La Sociedad anuncia la aprobación de Zepzelca® (lurbinectedina) para el tratamiento del cáncer de pulmón microcítico metastásico en Israel
Regulatory Filings Classification · 100% confidence The document is a formal communication dated January 31, 2023, addressed to the 'Comisión Nacional del Mercado de Valores' (CNMV - Spanish Securities Market Commission). It is titled 'OTRA INFORMACIÓN RELEVANTE' (OTHER RELEVANT INFORMATION) and announces that PharmaMar's partner received conditional marketing approval for Zepzelca® in Israel. Crucially, the first page states: 'Se adjunta nota de prensa que se distribuirá a los medios de comunicación en relación con esta noticia' (A press release that will be distributed to the media regarding this news is attached). The subsequent text is the full press release detailing the drug approval. Since the initial filing to the regulator is a brief notification stating that the detailed information (the press release) is attached/included, this structure strongly suggests a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS), rather than the comprehensive report itself (like 10-K or IR). Given that this is a specific announcement about a business event (drug approval) that is being disseminated via a press release, and the filing itself is the act of publishing that information to the market regulator, RPA is the most appropriate classification based on the 'MENU VS MEAL' rule, as the filing serves to publish the attached material.
2023-01-31 Spanish
La Sociedad anuncia la aprobación de Zepzelca® (lurbinectedina) para el tratamiento del cáncer de pulmón microcítico metastásico en México
Legal Proceedings Report Classification · 99% confidence The document is a formal communication dated January 24, 2023, addressed to the 'Comisión Nacional del Mercado de Valores' (Spanish Securities Market Commission). It explicitly states it is providing 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information) as required by Article 227 of the Spanish Securities Market Law. The content announces a regulatory/commercial milestone: the full marketing approval of Zepzelca® in Mexico by COFEPRIS. Crucially, the text states, 'Se adjunta nota de prensa que se distribuirá a los medios de comunicación en relación con esta noticia' (A press release that will be distributed to the media regarding this news is attached). This structure—a brief regulatory filing forwarding an attached press release about a business event—is characteristic of a general regulatory announcement that doesn't fit a specific financial report category (like 10-K, IR, or ER). Since it is a formal notification to the regulator about a significant event, and it is not a specific financial report, the most appropriate classification is the general regulatory filing category, RNS (Regulatory Filings), as it serves as the catch-all for such mandatory disclosures.
2023-01-24 Spanish

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.